Samuel Blackman is a distinguished figure in the biopharmaceutical industry, serving as the Co-Founder and Head of Research and Development at DAY ONE BIOPHARMACEUTICALS INC. With a robust background in oncology and molecular biology, Dr. Blackman has dedicated his career to advancing cancer research and developing innovative treatments. He earned his M.D. from the University of Pennsylvania and completed his residency and fellowship at the same institution, where he honed his expertise in pediatric oncology. His academic journey laid a solid foundation for his future contributions to the field. Prior to co-founding DAY ONE BIOPHARMACEUTICALS, Dr. Blackman held significant roles at leading biopharmaceutical companies, including Loxo Oncology and Novartis. At Loxo Oncology, he served as the Senior Vice President of Clinical Development, where he played a pivotal role in the development and FDA approval of several targeted cancer therapies. His work at Novartis further solidified his reputation as a leader in the development of novel cancer treatments. Dr. Blackman's extensive experience and strategic vision have been instrumental in driving DAY ONE BIOPHARMACEUTICALS' mission to develop transformative therapies for patients with life-threatening diseases, particularly those affecting children and young adults. In his current role at DAY ONE BIOPHARMACEUTICALS, Dr. Blackman oversees the company's research and development efforts, guiding the strategic direction of the company's pipeline. His leadership has been crucial in advancing the company's lead candidate, tovorafenib, a type II RAF inhibitor designed to treat pediatric low-grade glioma. Under his guidance, the company has made significant strides in clinical trials and regulatory submissions, positioning DAY ONE BIOPHARMACEUTICALS as a frontrunner in the development of targeted therapies for rare cancers. Dr. Blackman's dedication to improving patient outcomes and his commitment to scientific excellence continue to drive the company's success and its impact on the global fight against cancer.